Imatinib versus newer generation <scp>TKIs</scp> for upfront therapy in chronic phase <scp>chronic myeloid leukemia</scp>: What is the rationale for paying more to get the same survival benefit?

Authors:

Published: 0000-00-00

DOI: HTTPS://DOI.ORG/10.1002/ajh.27455

Keywords:

Abstract:

Source: